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asopressin Antagonism in Heart Failure
teven R. Goldsmith, MD,* Mihai Gheorghiade, MD†
inneapolis, Minnesota; and Chicago, Illinois
Treatment of chronic heart failure (HF) is based on interference with the renin-angiotensin-
aldosterone system and the adrenergic nervous system. Diuretics are used in volume-expanded
patients. Insights from clinical trials and registries establish the need to consider correcting
both cardiac loading conditions and nonload-related biological factors if HF therapy is to be
optimized. Arginine vasopressin (AVP) represents a potentially attractive target for therapy in
both acute and chronic HF. Excessive AVP secretion could contribute to both systolic and
diastolic wall stress via V1a- and V2-mediated effects on the peripheral vasculature and on
water retention. Arginine vasopressin also may directly and adversely affect myocardial
function due to the effect of V1a activation on myocardial contractility and cell growth. Last,
AVP may contribute to hyponatremia, a powerful predictor of poor outcome in HF. The
development of effective nonpeptide antagonists to both the V1a and V2 receptors for AVP
now allows for testing the hypotheses that interfering with AVP-mediated signaling could be
beneficial in HF. This review summarizes the theoretical rationale for further development of
such therapy, reviews the status of current compounds under development, and suggests key
issues that need to be addressed as these agents undergo further clinical testing. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.095Cardiol 2005;46:1785–91) © 2005 by the American College of Cardiology Foundation
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cherapy for chronic heart failure (HF) is currently based on
harmacologic interference with the renin-angiotensin-
ldosterone system (RAAS) and the adrenergic nervous
ystem, together with diuretics as needed. This treatment
as reduced the expected annualized mortality in HF to 5%
o 6% per year in stable, well-compensated patients (1,2).
here are, however, many patients who clearly need addi-
ional support. Such patients are characterized by persistent
ongestion, frequent readmissions, renal failure, and hypo-
atremia (3–6).
Acute decompensated heart failure (ADHF) also remains
challenge. Data from the Acute Decompensated Heart
ailure National registry (ADHERE) show that shortness
f breath and edema are the major causes for admission to
he hospital in patients with known HF (6). Therapy for
DHF is frequently suboptimal, with 60-day readmission
ates in the range of 17% to 22% and 60-day mortality as
igh as 22% in patients with severe congestion and/or even
ild renal impairment (5). Loop diuretics remain the prime
ntervention in ADHF. While retrospective data suggest
etter outcomes in patients treated with vasodilators as
ompared to inotropes (6), and while one vasodilator,
esiritide, may be less arrhythmogenic than dobutamine (7)
nd marginally superior to low-dose nitroglyerin for symp-
om relief (8), no additional therapy has yet been proven to
e of adjunctive value in outcomes-driven prospective,
lacebo-controlled trials. The patient with renal insuffi-
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005, accepted February 14, 2005.iency remains a challenge, even with the use of newer
reatments like nesiritide (9).
In view of the success of neurohormonally guided treat-
ent, further exploitation of this approach seems reason-
ble, both for chronic and acute HF. In theory, the
ntidiuretic hormone arginine vasopressin (AVP) is an
ttractive target, but until recently there have not been
ffective intravenous and oral antagonists to its effects. The
ecent development of such agents provides the opportunity
o test the possibility that interference with AVP might be
seful in the treatment of HF.
VP IN HF
reatment of chronic HF clearly needs to include both
ptimizing cardiac loading conditions, and the correction of
onload-related variables that contribute to progressive
entricular remodeling and failure (10). At least some of
hese variables must be improved by angiotensin-converting
nzyme inhibition, angiotensin receptor blockade, beta-
drenergic blockade, and aldosterone antagonists because
hese treatments improve the outcome in HF despite
inimal if any effects on loading conditions or hemody-
amics. Comprehensive neurohormonal inhibition actually
mproves the basic biology of the heart, including partial
eversal of the ventricular remodeling process at both the
henotypic and genotypic levels (11,12).
Similar considerations may apply to ADHF. Although
here are far fewer data, the routine use of inotropic support
s not supported by available trials (13), and there are no true
utcomes studies with any vasodilator. Diuresis remains the
ey intervention for most patients with ADHF, yet diuretics
an produce harm both acutely and chronically via electro-
yte disturbances, neurohormonal stimulation, and worsen-
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Vasopressin Antagonism in HF November 15, 2005:1785–91ng renal function (14–16). Diuretics have been reported to
ctually hasten the development of overt HF in experimen-
al HF (17), and the intensity of their use in chronic HF is
ssociated with poor outcome (18).
Arginine vasopressin was one of the candidate “patho-
ens” in the original paper describing the “neurohumoral
xis” in HF (19). Arginine vasopressin is a nonapeptide
ynthesized in the hypothalamus, stored in the posterior
ituitary for release in response to both osmotic and
onosmotic factors. The dominant stimulus for AVP secre-
ion in all species is serum osmolality (20). Nonosmotic
actors including cardiac filling pressure, arterial pressure,
nd other influences, such as the effects of adrenergic stimuli
nd angiotensin II in the central nervous system, all can
odulate the osmotic control of AVP to varying degrees in
ifferent species (20).
For reasons as yet unexplained, plasma AVP levels are
nappropriately high in both acute and chronic HF (21–25).
n early study with a bioassay showed elevated AVP in
atients with HF due to a mix of etiologies (21). Later,
adioimmunoassays of AVP in patients with both stable HF
nd ADHF associated with left ventricular systolic dysfunc-
ion confirmed frankly elevated or incompletely suppressed
VP levels (22–25). These reports were before the intro-
uction of converting enzyme inhibitors and beta-blockers,
owever, and a recent study described plasma AVP levels in
table chronic HF patients that were lower than in the
arlier work (26). No recent data regarding AVP levels in
DHF have been published.
Plasma AVP is elevated in the presence of left ventricular
ysfunction even in the absence of clinical HF (27). As with
ther neurohormones, elevated plasma AVP correlates with
oor outcomes (28). If the therapeutic experiences with the
AAS and the adrenergic nervous system are predictive,
xcessive AVP secretion may prove to be a contributor to
he syndrome and not just a marker of severity.
Arginine vasopressin has many effects. Its major actions
elevant to HF relate to signaling at the V1a and V2
eceptors (29) (Table 1). The V1a receptor is a G-protein–
Abbreviations and Acronyms
ADHF acute decompensated heart failure
AVP  arginine vasopressin
HF  heart failure
RAAS  renin-angiotensin-aldosterone system
able 1. Actions of Vasopressin
Receptor Signaling Location Actions
1a G-protein, IP3 Blood vessels Vasoconstriction
Myocardium Inotrope/mitogen
2 Adenyl cyclase Renal tubule H2O retention
Endothelium Vasodilation (high
concentrations)o
he predominant actions of vasopressin as relates to heart failure involve activation of
he V1a and V2 receptors. See text for details.oupled receptor which, when activated, increases intracel-
ular calcium through the inositol triphosphate pathway
30). The result is constriction of smooth muscle (30) and a
ositive inotropic effect in cardiac muscle (31). Prolonged
1a stimulation leads to synthesis of proteins involved in
ellular hypertrophy both in vascular and myocardial tissue
32).
Activation of the V2 receptor alters the expression of
quaporin channels and thereby increases the permeabil-
ty to water of the renal collecting tubular cells (33),
esulting in water retention. V2 receptors may also subserve
ndothelium-dependent vasodilation, but probably not at
ormal physiologic levels (34).
Excess AVP secretion could contribute to the pathophys-
ology of HF by several distinct load-dependent and load-
ndependent mechanisms (29) (Fig. 1). V1a receptor stim-
lation could cause constriction of both arteries and veins
nd so contribute to increased myocardial afterload and
reload. Increases in loading conditions may contribute to
entricular remodeling and progressive HF. Sustained V1a
timulation could also directly contribute to myocardial
ypertrophy and aggravate adverse remodeling. Because the
ntracellular signaling pathway for the V1a receptor resem-
les that for angiotensin II, any adverse myocardial and
ascular effects from V1a stimulation would likely be more
rominent in the presence of agents that interfere with the
eneration or effects of angiotensin II. V1a stimulation
ould also cause coronary vasoconstriction and contribute to
yocardial ischemia. Recently, an endothelium-dependent
echanism by which AVP may be synthesized in the heart
as been described (35). If this can be confirmed in humans,
lasma levels of AVP might underestimate the magnitude
f V1a-mediated myocardial and coronary effects. There
ay be an interesting parallel here with the systemic and
igure 1. Vasopressin could aggravate the progression of heart failure by
dversely affecting ventricular remodeling, worsening clinical congestion,
nd contributing to hyponatremia. V1a effects would be predominantly
hose causing arterial vasoconstriction, increasing afterload, and adversely
ffecting ventricular structure and function. Direct myocardial V1a effects
ould also be present. V2 effects could lead to excessive circulatory
ongestion, adversely affecting myocardial structure and function via
ncreasing preload. V2 effects would also lead to hyponatremia. AVP 
rginine vasopressin; LV  left ventricular.rgan-specific synthesis of angiotensin II.
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November 15, 2005:1785–91 Vasopressin Antagonism in HFThe V2 receptor stimulation by AVP could contribute to
olume expansion and therefore to increased cardiac pre-
oad. Increased preload exacerbates diastolic wall stress, in
urn aggravating eccentric remodeling. If water accumulates
o a greater degree than sodium, hyponatremia results.
yponatremia is a marker for poor outcome in HF, even in
he modern era (5). While generally assumed to be simply a
arker for advanced disease, hyponatremia could be an
ctive contributor to both morbidity and perhaps disease
rogression. For example, the only available treatment for
yponatremia is water restriction, which is often poorly
olerated by sick patients, thereby adversely affecting quality
f life. Hyponatremia may have another more insidious
ontribution to poor outcome in severe HF by limiting the
ntensity of therapy with diuretics, angiotensin-converting
nzyme inhibitors, and angiotension receptor blockers. And
yponatremia could theoretically adversely affect myocyte
unction via increased cellular water content, as happens in
he brain. An extremely provocative recent investigation
eported that chronically correcting serum sodium with the
ombination of hypertonic saline and loop diuretics was
ssociated with improved outcome in a population of
atients with very severe HF (36). This study should
ertainly prompt further investigation of the nature of the
elationship between hyponatremia and poor outcome
n HF.
XPERIMENTAL STUDIES OF AVP ANTAGONISM
cute V1a antagonism produces hemodynamic improve-
ent in animal models of HF (37–39). There is currently no
ong-term experience with a pure V1a antagonist. Most
tudies have involved only the use of the V1a antagonist, but
ne (in the pacing model) demonstrated synergism with the
ombination of a V1a antagonist and an angiotensin II
ntagonist (40). This is a potentially important observation
n view of the common intracellular signaling pathways for
VP and angiotensin II. As well, many prior studies
onducted under other conditions consistently showed more
otent effects of V1a antagonism in the absence of activity
f the adrenergic nervous system and the RAAS (41–43).
Administration of a V2 antagonist in animal models of
F yields a sustained diuresis that is largely an “aquaresis”
44). Combined administration of V1a and V2 antagonists
n the pacing model of HF and the use of a mixed V1a/V2
ntagonist in the postmyocardial infarction rat model of HF
ave resulted in greater hemodynamic benefit than with
elective antagonism (39,45–47). When given chronically in
xperimental postmyocardial infarction HF, a combined
1a/V2 antagonist produced significant effects on right
entricular, but not left ventricular, weight beyond that seen
ith an angiotensin-converting enzyme inhibitor (48). The
vailable experimental literature, while sparse, therefore
uggests active V1a and V2 signaling in models of left
entricular dysfunction and HF. (UMAN STUDIES
1 antagonists. Infusion of exogenous AVP in patients
ith chronic stable HF produced acute hemodynamic de-
erioration, presumably via V1a effects (49) (Fig. 2). Single-
ose studies with an intravenous peptide V1a antagonist
howed evidence of V1a signaling by demonstrating a fall in
ystemic vascular resistance and improvement in cardiac
utput in HF patients with elevated AVP levels (50).
dministration of the same V1a antagonist also reduced
lood pressure in patients with resistant hypertension,
espite relatively low AVP levels (51). This was an impor-
ant observation because it suggests that, especially in the
ace of other vasoactive treatments, plasma levels of AVP
ay not predict the hemodynamic response to an effective
ntagonist.
Development of nonpeptide V1a antagonists has been
ifficult, because compounds that have seemed promising in
nimals have been shown to be partial agonists in humans
52). Preliminary work has been done with relcovaptan (SR
9059, Sanofi Recherche, Paris, France) (53), in both
ypertension and HF, but there is no published information
egarding these studies, and the compound is not currently
ndergoing further clinical evaluation. As of this writing,
e know of no other pure V1a antagonist being devel-
ped for HF.
2 antagonists. The issue of species-dependent partial
gonism has also plagued the development of V2 antago-
ists. However, several effective agents have been tested
33). Lixivaptan (VPA 459, originally Wyeth-Ayerst, now
ardiokine, Philadelphia, Pennsylvania), tolvaptan (OPC-
1061, Otsuka, Rockville, Maryland), and SR 121463
igure 2. Hemodynamic effects of infused arginine vasopressin (AVP) in
atients with chronic heart failure. CO cardiac output; HR heart rate;
AP  mean arterial pressure; PCWP  pulmonary capillary wedge
ressure; SV  stroke volume; SVR  systemic vascular resistance. *p 
.01; †p  0.05. Adapted from Goldsmith SR, et al. J Am Coll Cardiol
986;8:779–83.Sanofi Recherche) have all been investigated in phase I and
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Vasopressin Antagonism in HF November 15, 2005:1785–91I trials. Tolvaptan is now in phase III studies for both HF
nd hyponatremia.
Acute and chronic studies with these agents in patients
ith HF demonstrate brisk and sustained increases in urine
utput and free water clearance (54,55), thereby establishing
he presence of clinically measurable V2 signaling in human
F. The V2 antagonists may be viewed as the first new class
f diuretic agents since the development of furosemide, but
hey are “aquaretics,” not “saliuretics.” With time, osmotic
hifts lead to modest sodium excretion, but the predominant
ffect remains water excretion. There is no depletion of
ther electrolytes, and, in experimental studies, less stimu-
ation of renin, aldosterone, and catecholamines than is seen
ith a comparable diuresis produced by furosemide (56).
Only one of these compounds, tolvaptan, has thus far
een studied for longer than a few days in humans. The
rug was given for 30 days to patients with mild clinical HF
f diverse etiologies, some with hyponatremia (54). A
ustained water diuresis was achieved, with body weight
emaining below baseline, and only a modest, if any, rise in
igure 3. Effects of tolvaptan relative to placebo on body weight at 24 h (the
rimary end point of the study) and at discharge in the Acute and Chronic
herapeutic Impact of a Vasopressin (ACTIV) trial. *p  0.05 vs. placebo.
dapted from reference 55. White bars  placebo; black bars  tolvaptan 0
g; dotted bars  tolvaptan 60 mg; grey bars  tolvaptan 90 mg.igure 4. Effect of tolvaptan on serum sodium in those patients presenting with in
f a Vasopressin (ACTIV) trial. Adapted from reference 55. White bars  placeberum sodium for the group as a whole. Patients who were
yponatremic maintained an improvement in serum so-
ium. The drug was well tolerated, with thirst the only
ajor side effect reported.
A subsequent investigation with tolvaptan focused on
atients with ADHF with ejection fraction less than 40%.
his investigation, Acute and Chronic Therapeutic Impact
f a Vasopressin Antagonist in Congestive Heart Failure
ACTIV in CHF) (55), was placebo-controlled, included a
0 day follow-up, and had two primary end points: 1)
n-hospital body weight 24 h after drug administration; and
) worsening HF at 60 days. There was a significantly
reater reduction in body weight during the first 24 h in the
roup receiving tolvaptan. The body weight further de-
reased by discharge in the tolvaptan groups (Fig. 3). This
ifference was maintained during follow-up. However,
hile body weight declined on tolvaptan, there were no
tatistically significant differences in the signs and symptoms
f clinical congestion. At 60 days, there was no difference in
orsening HF between the groups. Patients randomized to
olvaptan used less furosemide and maintained a lower body
eight, and there were no differences in heart rate, blood
ressure, or renal function. If serum sodium was low, it
ormalized and remained so throughout the study period
Fig. 4). Although not powered for mortality, an intriguing
ost-hoc analysis suggested a reduction in mortality in the
igher-risk patients (those with “severe” congestion and/or
lood urea nitrogen 29 mg/dl).
There were significant side effects reported during the
tudy with drop-out rates of nearly 33% in patients assigned
o tolvaptan (for a variety of reasons, although excessive
hirst was common). While AVP levels from the two arms
f the study have not yet been reported, and while there was
o worsening of HF in either arm of the study, it is
nteresting that while body weight decreased on activeitial sodium under 135 mEq/ in the Acute and Chronic Therapeutic Impact
o; black bars  30 mg; dotted bars  60 mg; grey bars  90 mg.
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November 15, 2005:1785–91 Vasopressin Antagonism in HFreatment, blood pressure did not fall. This is unusual
ith significant diuresis in HF, and could suggest the
nmasking of a V1a effect from endogenously stimulated
VP.
These results, while provocative and raising some unan-
wered questions, led to the initiation of a mortality trial of
olvaptan, which began enrollment in late 2003 (Efficacy of
asopressin Antagonism in Heart Failure: Outcome Study
ith Tolvaptan [EVEREST]). The results of a phase II trial
ith this compound, in which ventricular remodeling was
he primary end point, were presented at a “Late-Breaking
rials” session during the meeting of the Heart Failure
ociety of America in September 2005. The results did not
how a beneficial effect of tolvaptan on ventricular remod-
ling versus placebo after approximately one year of treat-
ent. However, the drug was well-tolerated, and a post-hoc
aplan-Meier analysis of time to readmission or death was
avorable for the tolvaptan group (Udelson et al., unpub-
ished data, September 2005).
ombined V1a/V2 antagonists. To date, only one effec-
ive combined V1a/V2 antagonist (Conivaptan, or YM087,
amanouchi Pharma, Surrey, United Kingdom) (57) has
een evaluated in humans. This compound has demon-
trated not only V1a- and V2-blocking effects in the
eripheral circulation and kidney (57), but also the ability to
lock the recently described myocellular effects of V1a
timulation (58). Phase III trials have been completed with
onivaptan in hyponatremia with a pending application to
he Food and Drug Administration for approval. The V1a
eceptor antagonism of the compound would not be ex-
ected to contribute directly to an effect on hyponatremia,
ut, because many patients with hyponatremia have HF, if
1a signaling is important, this could be viewed as an added
enefit.
There is as yet limited information regarding this com-
ound in patients with HF. A large single-dose experience
n patients with chronic stable HF showed that acute
dministration of conivaptan produced a fall in cardiac
lling pressures together with a water diuresis (26). There
ere no effects of the compound on blood pressure, cardiac
utput, or systemic vascular resistance, suggesting that the
redominant effect may have been V2 receptor-related. The
atients studied had relatively normal AVP levels, however,
aking it less likely that a major V1a effect would be seen
cutely. And it is not clear whether the early fall in filling
ressures could be accounted for solely by the diuretic effect.
f filling pressures declined before diuresis, a venorelaxant
ffect could have occurred. A positive effect on cardiac
utput could also have been masked by a preload-related
ecline in stroke volume. Interpreting these hemodynamic
esults is therefore complicated, but it is clear that the acute
dministration of this compound reduces cardiac filling
ressures and causes an aquaresis. Current plans for convi-
atan are focused on treatment for ADHF, and hyponatre-
ia, but only for acute use in view of significant cytochrome
450 interactions. A phase II pilot trial in ADHF has been mompleted with the results to be available in 2005, while
ositive results in phase III hyponatremia trials (59) have led
o an active new drug application with a response expected
n late 2005. Many of the patients in those phase III trials
ad HF, so more information about the effect of conivaptan
n HF should be forthcoming from the detailed analysis of
hat experience.
ATHOPHYSIOLOGIC AND PRACTICAL
ONSIDERATIONS FOR FUTURE STUDIES
ecause effective antagonists of both the V1a and V2
eceptors are now available, several key issues must be
onsidered in their future development. Clearly, both V1a-
nd V2-mediated effects are demonstrable in severe and/or
ecompensated HF; therefore it is reasonable to consider
ither or both types of antagonists in these settings. A pure
1a antagonist might produce arterial vasodilation, acute
emodynamic improvement, and, chronically, a reduced
fterload-related stimulus to ventricular remodeling. It
ight also diminish venoconstriction and adverse direct
yocardial stimulation from AVP. All V1a effects may be
ore important in the setting of other neurohormonal
ntagonists. However, if plasma AVP levels rose in the
resence of a competitive V1a antagonist, unwanted water
etention could occur, with either congestion or hyponatre-
ia or both as a consequence. On the other hand, while a
ure V2 antagonist will produce a sustained aquaresis, if
VP levels increased in response to the presence of a
ompetitive antagonist, or due to increased osmolality,
nwanted acute vasoconstriction and/or direct myocardial
timulation from V1a activation might occur.
The foregoing considerations may favor the use of com-
ined antagonists, both for acute and chronic HF, although
he relative contribution of each type of receptor antagonist
ight vary depending on the setting in which it is evaluated.
hen evaluating the long-term effects of selective antago-
ists, it might be helpful to carefully assess the impact of
uch agents on plasma AVP levels and AVP-mediated
ignaling at the unblocked receptor sites. Such studies
ould enhance understanding of the full physiologic effects
f these agents, and address the issues mentioned regarding
afety.
The rationale for acute and chronic use of a V1a antag-
nist is straightforward. The rationale for acute use of V2
ntagonists is also obvious: the rationale supporting the
hronic use of such agents, unless in the setting of persistent
ongestion, perhaps less so, but worth considering. First,
here may simply be a beneficial effect on preventing
ongestion, alone or in combination with loop diuretics.
learly, persistent congestion is a major clinical issue for
any patients, and a major indicator of poor outcome
6,55). The clinical trials and registries indicate that pre-
ention and relief of congestion is currently suboptimal.
educing congestion would obviously be desirable to reduce
orbidity and expense, but as well might reduce the
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Vasopressin Antagonism in HF November 15, 2005:1785–91timulus for maladaptive ventricular remodeling from exces-
ive preload. An effective aquaretic agent might also lead to
more effective overall diuresis by rapidly encouraging the
ovement of water and then electrolyte out of cells into the
ascular space and so ultimately to the kidney where it may
e excreted. The net result might be an effect on total body
ongestion and ventricular preload produced more easily
han with the isotonic diuresis produced by loop diuretics
lone.
Next, as discussed in the previous text, there are demon-
trable adverse effects of high doses of loop diuretics on
lectrolytes, neurohormonal balance, and renal function
14–16). High-dose diuretic use is also correlated with poor
utcome in HF (18). It is therefore possible that a loop-
iuretic-sparing effect as a result of V2 antagonism could
ead to a safer, as well as a more effective, reduction in
entricular preload. Combining a V2 antagonist with other
ewer approaches such as natriuretic peptides and/or aden-
sine antagonists could, in theory, lead to even less reliance
n loop diuretics, especially in the setting of renal insuffi-
iency (16).
Lastly, effective V2 antagonists would be of significant
otential benefit in patients with HF and hyponatremia. As
lready discussed, hyponatremia, even mild hyponatremia,
onfers a significantly worse outcome in HF (5), and it may
e that safely and simply correcting this condition could
mprove outcomes in this group of patients.
ONCLUSIONS
he development of AVP antagonists for acute and chronic
F rests on a strong theoretical basis, but there are
mportant unanswered questions and unresolved issues.
erely demonstrating a desirable pharmacologic effect is
ot sufficient to warrant adoption of a new class of therapy
or either acute or chronic HF. The benchmark for chronic
se is either a positive effect on mortality, or at least a strong
ffect on morbidity with neutral effects on mortality. There
s currently no consensus for what constitutes a rationale for
dopting a new treatment for ADHF, but it will undoubt-
dly become necessary to meet some combination of clini-
al, biological, and economic end points. At a minimum,
uch treatment should acutely improve the clinical status of
atients (i.e., congestion) while not adversely affecting
iological variables known to be associated with poor
utcome. It is also critical that no delayed adverse effects on
ortality or morbidity be seen. For all of the reasons
iscussed in this review, it should be clear that targeting
VP has the real potential to be a useful additional therapy
n both acute and chronic HF.
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ark Avenue South, Orange 5, Minneapolis, Minnesota. E-mail:
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